Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue Medication
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer, Prostatic Neoplasms
Trial Timeline
May 13, 2025 → Jan 6, 2031
NCT ID
NCT06925737About Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue Medication
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue Medication is a phase 3 stage product being developed by Daiichi Sankyo for Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06925737. Target conditions include Prostate Cancer, Prostatic Neoplasms.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06925737 | Phase 3 | Recruiting |
Competing Products
20 competing products in Prostate Cancer